![]() |
21st August 2008 @ 4:57am |
| Subscribe | Instructions To Authors | Advertising/Supplements | Contact Us | Help |
|
Volume 3, Number 3, December 2006Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy Asubstantial number of individuals with type 2 diabetes
mellitus (T2DM) demonstrate a predominance
of small dense low-density lipoprotein (sdLDL),
which is associated with an increased risk of cardiovascular
disease (CVD). In some cases, sdLDL persists after treatment
with a statin to reduce levels of LDL. The effect of the
addition of a thiazolidinedione, rosiglitazone (RSG)
(4 mg/day or 8 mg/day) to statin therapy on LDL phenotype
and C reactive protein (CRP) levels was investigated in a 12-
week, placebo-controlled study of 72 T2DM patients who
were well controlled and on a statin, but who had persistently
predominant sdLDL. Diabetes Vasc Dis Res 2006;3:189-196. View full PDF article (open in new window) Right click on this DOI link and copy link to cite this article (What is a DOI link?) |